Apart from the low agonistic activity of these first-generation TRAs as compared to high-activity forms of TRAIL, some of which had been known since the initial in-vivo studies with this cytokine [9, 11], the other main reason for this failure is likely the resistance of most primary cancer cells to TRAIL-induced apoptosis [11–13]. Here, TNFSF10 is linked to cancer.